You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Microsatellite instability

Showing 26 - 50 of 1,595
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Advanced or Metastatic Solid Tumors, Microsatellite Instability Low, Microsatellite Instability High Trial in United States

Recruiting
  • Advanced or Metastatic Solid Tumors
  • +11 more
  • Tucson, Arizona
  • +11 more
Dec 2, 2022

NSCLC, Cutaneous Melanoma, Carcinoma, Renal Cell Trial (KFA115, tislelizumab)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • +10 more
  • Singapore, Singapore
    Novartis Investigative Site
Nov 16, 2022

Advanced Solid Tumors, Lymphoma, Gastric Cancer Trial in United States (FT500, Nivolumab, Pembrolizumab)

Completed
  • Advanced Solid Tumors
  • +17 more
  • San Diego, California
  • +3 more
Jan 27, 2023

Carcinoma, Renal Cell, Head and Neck Tumor, Skin Tumors Trial in Villejuif (Nivolumab)

Active, not recruiting
  • Carcinoma, Renal Cell
  • +5 more
  • Villejuif, France
    Gustave Roussy Cancer Campus
Mar 28, 2022

Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

Recruiting
  • Colorectal Carcinoma
  • Guangzhou, China
    Sun Yat-sen University
Dec 29, 2022

Solid Tumor Trial in Beijing (KN035)

Recruiting
  • Solid Tumor
  • KN035
  • Beijing, Beijing, China
    Peking University Cancer Hospital, Peking University
Apr 5, 2022

MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

Not yet recruiting
  • MSI-H
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 26, 2023

Melanoma, Non-small Cell Lung Carcinoma (NSCLC), Renal Cell Carcinoma (RCC) Trial in Gainesville, Jacksonville (LITT +

Recruiting
  • Melanoma
  • +14 more
  • LITT + Pembrolizumab
  • Gainesville, Florida
  • +1 more
Aug 22, 2022

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

Solid Tumor, Microsatellite Instability, Mismatch Repair Deficiency Trial in Australia (APL-501)

Completed
  • Solid Tumor
  • +3 more
  • Camperdown, New South Wales, Australia
  • +4 more
May 5, 2022

Melanoma, NSCLC, Hepatocellular Carcinoma Trial in Pittsburgh (Nivolumab or Pembrolizumab (dependent upon approved indication),

Recruiting
  • Melanoma
  • +7 more
  • Nivolumab or Pembrolizumab (dependent upon approved indication)
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Feb 10, 2022

Advanced Solid Tumor, Non Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma Trial in United States (STK-012,

Recruiting
  • Advanced Solid Tumor
  • +10 more
  • Boston, Massachusetts
  • +8 more
Jan 2, 2023

Colorectal Carcinoma Trial (Pembrolizumab)

Completed
Has Results
  • Colorectal Carcinoma
  • Pembrolizumab
  • (no location specified)
Mar 29, 2022

Colon Cancer Trial (Tislelizumab)

Not yet recruiting
  • Colon Cancer
  • (no location specified)
Feb 7, 2022

MSI-H/dMMR Solid Tumor Trial in Guangzhou (AK104)

Terminated
  • MSI-H/dMMR Solid Tumor
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Oct 17, 2022

Melanoma, Lymphoma, Solid Tumor Trial in Worldwide (Pembrolizumab)

Recruiting
  • Melanoma
  • +4 more
  • Pembrolizumab
  • Aurora, Colorado
  • +18 more
Jan 5, 2023

Solid Tumors, Identified by NGS, PCR or IHC Trial in United States (Pembrolizumab)

Recruiting
  • Solid Tumors
  • Identified by NGS, PCR or IHC
  • Basking Ridge, New Jersey
  • +6 more
Oct 7, 2022

Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • HX008
  • Investigator's Choice Chemotherapy
  • Hefei, Anhui, China
  • +9 more
Dec 8, 2022

Colorectal Cancer Trial in China (Tislelizumab)

Recruiting
  • Colorectal Cancer
  • Bengbu, Anhui, China
  • +7 more
Sep 13, 2022

Solid Tumor, Microsatellite Instability-High (MSI-H) Solid Tumors, Cutaneous Melanoma Trial in Worldwide (LY3300054,

Active, not recruiting
  • Solid Tumor
  • +4 more
  • Nashville, Tennessee
  • +14 more
Jul 21, 2022

Localized Oesogastric Adenocarcimona, MSI and or dMMR Trial in France (Nivolumab 10 MG/ML, Ipilimumab 200 MG in 40 ML Injection)

Recruiting
  • Localized Oesogastric Adenocarcimona
  • MSI and or dMMR
  • Nivolumab 10 MG/ML
  • Ipilimumab 200 MG in 40 ML Injection
  • Besançon, France
  • +14 more
Jun 10, 2021

Long-term, Non-interventional, Observational Study Following

Recruiting
  • Advanced Solid Tumor
  • +17 more
  • Allogeneic natural killer (NK) cell
  • San Diego, California
  • +3 more
Oct 15, 2021

s Microsatellite Instability Testing v Mismatch Repair in

Completed
  • Gastric Cancer
  • Mismatch repair
  • Truro, Cornwall, United Kingdom
    Royal Cornwall Hospital
Oct 6, 2020

Thyroid, Renal Cell Carcinoma, Non Small Cell Lung Cancer Trial in Worldwide (SO-C101, pembrolizumab)

Recruiting
  • Thyroid
  • +18 more
  • New Haven, Connecticut
  • +6 more
Apr 8, 2022

Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, MSI High Colorectal Cancer Trial in Boston (Nivolumab, Ipilimumab,

Recruiting
  • Microsatellite Stable Colorectal Cancer
  • +2 more
  • Boston, Massachusetts
    Massachusetts general Hospital
Mar 24, 2021